CN112245419A - 包括15-hepe的组合物以及使用其治疗或预防纤维化的方法 - Google Patents

包括15-hepe的组合物以及使用其治疗或预防纤维化的方法 Download PDF

Info

Publication number
CN112245419A
CN112245419A CN202011279675.6A CN202011279675A CN112245419A CN 112245419 A CN112245419 A CN 112245419A CN 202011279675 A CN202011279675 A CN 202011279675A CN 112245419 A CN112245419 A CN 112245419A
Authority
CN
China
Prior art keywords
hepe
agent
fibrosis
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011279675.6A
Other languages
English (en)
Chinese (zh)
Inventor
J·罗
K·杜菲
J·克莱麦克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Efimoen GmbH
Original Assignee
Efimoen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efimoen GmbH filed Critical Efimoen GmbH
Publication of CN112245419A publication Critical patent/CN112245419A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202011279675.6A 2014-12-02 2015-12-02 包括15-hepe的组合物以及使用其治疗或预防纤维化的方法 Pending CN112245419A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086535P 2014-12-02 2014-12-02
US62/086,535 2014-12-02
CN201580074543.0A CN107206008A (zh) 2014-12-02 2015-12-02 包括15‑hepe的组合物以及使用其治疗或预防纤维化的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580074543.0A Division CN107206008A (zh) 2014-12-02 2015-12-02 包括15‑hepe的组合物以及使用其治疗或预防纤维化的方法

Publications (1)

Publication Number Publication Date
CN112245419A true CN112245419A (zh) 2021-01-22

Family

ID=56092410

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011279675.6A Pending CN112245419A (zh) 2014-12-02 2015-12-02 包括15-hepe的组合物以及使用其治疗或预防纤维化的方法
CN201580074543.0A Pending CN107206008A (zh) 2014-12-02 2015-12-02 包括15‑hepe的组合物以及使用其治疗或预防纤维化的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580074543.0A Pending CN107206008A (zh) 2014-12-02 2015-12-02 包括15‑hepe的组合物以及使用其治疗或预防纤维化的方法

Country Status (17)

Country Link
US (1) US10363235B2 (https=)
EP (2) EP3988101A1 (https=)
JP (2) JP6986445B2 (https=)
KR (1) KR20170102879A (https=)
CN (2) CN112245419A (https=)
AU (2) AU2015358512B2 (https=)
BR (1) BR112017011685A2 (https=)
CA (1) CA2968980A1 (https=)
ES (1) ES2900593T3 (https=)
IL (2) IL252431B (https=)
MA (1) MA41120A (https=)
MX (2) MX382116B (https=)
PH (1) PH12017501022B1 (https=)
RU (2) RU2020115523A (https=)
SG (2) SG10202010594WA (https=)
WO (1) WO2016090030A1 (https=)
ZA (2) ZA201704463B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
SG10202000496XA (en) * 2014-01-10 2020-03-30 Afimmune Ltd Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EP3247348A1 (en) * 2015-01-16 2017-11-29 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CN117402059A (zh) 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
KR20180094516A (ko) * 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
US20140079631A1 (en) * 2011-03-25 2014-03-20 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
WO2014118097A1 (en) * 2013-01-30 2014-08-07 Dignity Sciences Limited Compositions comprising 15-ohepa and methods of using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
WO2001049282A2 (en) * 2000-01-06 2001-07-12 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
BRPI0715402A2 (pt) * 2006-08-08 2013-11-26 Lipomics Technologies Inc Marcadores de doença hepática gordurosa não alcoólica (nafld) e esteatohepatite não alcoólica (nash) e métodos de uso dos mesmos
US8042070B2 (en) * 2007-10-23 2011-10-18 International Business Machines Corporation Methods and system for analysis and management of parametric yield
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
ES2869884T3 (es) * 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
SG11201401629XA (en) 2011-10-19 2014-05-29 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
SG11201402653QA (en) 2011-11-29 2014-06-27 Dignity Sciences Ltd Compositions comprising 20-carbon fatty acids and methods of making and using same
KR20150028761A (ko) * 2011-12-16 2015-03-16 타릭스 파마슈티컬스 엘티디. 섬유증 치료용 안지오텐신
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da) 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
US20140079631A1 (en) * 2011-03-25 2014-03-20 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
WO2014118097A1 (en) * 2013-01-30 2014-08-07 Dignity Sciences Limited Compositions comprising 15-ohepa and methods of using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
沈毅慧等: "替米沙坦对大鼠非酒精性脂肪性肝炎肝纤维化的影响", 《胃肠病学和肝病学杂志》 *
王凯等: "《简明临床肝病学》", 30 November 2010, 山东大学出版社出版 *

Also Published As

Publication number Publication date
US20160184252A1 (en) 2016-06-30
RU2020115523A (ru) 2021-01-27
PH12017501022B1 (en) 2022-02-16
MX2017007000A (es) 2017-12-07
IL252431A0 (en) 2017-07-31
PH12017501022A1 (en) 2017-11-27
CN107206008A (zh) 2017-09-26
WO2016090030A1 (en) 2016-06-09
MA41120A (fr) 2017-10-10
EP3988101A1 (en) 2022-04-27
EP3226873A1 (en) 2017-10-11
MX382116B (es) 2025-03-13
JP2022031813A (ja) 2022-02-22
KR20170102879A (ko) 2017-09-12
ZA201704463B (en) 2018-11-28
CA2968980A1 (en) 2016-06-09
IL287983A (en) 2022-01-01
SG11201704495VA (en) 2017-06-29
ES2900593T3 (es) 2022-03-17
MX2021005080A (es) 2021-06-15
US10363235B2 (en) 2019-07-30
EP3226873A4 (en) 2018-08-08
JP6986445B2 (ja) 2021-12-22
BR112017011685A2 (pt) 2018-01-02
JP2017536380A (ja) 2017-12-07
AU2015358512B2 (en) 2021-02-18
ZA201804380B (en) 2021-03-31
HK1245101A1 (zh) 2018-08-24
SG10202010594WA (en) 2020-12-30
RU2721555C2 (ru) 2020-05-20
RU2017122758A (ru) 2019-01-09
AU2021203189A1 (en) 2021-06-10
RU2017122758A3 (https=) 2019-06-13
EP3226873B1 (en) 2021-10-27
AU2015358512A1 (en) 2017-07-20
IL252431B (en) 2021-12-01

Similar Documents

Publication Publication Date Title
CN112245419A (zh) 包括15-hepe的组合物以及使用其治疗或预防纤维化的方法
CN105120872B (zh) 包含15-hepe的组合物以及其使用方法
JP2018514534A5 (https=)
JP2023153863A (ja) １５－ｈｅｐｅを含む組成物及びその使用方法
JP7229285B2 (ja) １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
ES3026786T3 (en) Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease
US20250367229A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
CN113893240A (zh) 包含15-hepe的组合物和其使用方法
HK1245101B (en) Compositions comprising 15-hepe and its use for treating or preventing idiopathic pulomonary fibrosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210122